Clinical Program Operations Manager, Therapeutics & Innovations
NateraSalary not specified
- Full Time
- Senior (5 to 8 years)
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries
Requirements
Candidates should possess a Bachelor's degree in a related field, such as Business Administration, Project Management, or a scientific discipline, and ideally have 8+ years of experience in program management, particularly within the pharmaceutical or biotechnology industry. Strong leadership, communication, and stakeholder management skills are essential, along with a demonstrated ability to manage complex projects and drive results. Experience with cross-functional teams and matrix organizations is highly desirable.
Responsibilities
The Director, Program Management will lead the operations of one or more cross-functional teams, focusing on priorities, goal achievement, and resource allocation, while fostering a collaborative and sustainable team environment. They will partner closely with the Program Team Leader and subject matter experts to ensure comprehensive program plans are developed and executed effectively, incorporating agile methodologies to adapt to emerging data. The role involves facilitating discussions, eliciting recommendations, and managing stakeholders at all levels of the company, with a focus on achieving strategic development goals and maintaining a patient-focused approach.
Skills
Program Management
Cross-functional Collaboration
Project Planning
Risk Management
Agile Methodology
Stakeholder Engagement
Decision-Making
Data-Driven Adaptability
Dyno Therapeutics
Develops AI-optimized gene therapy vectors
About Dyno Therapeutics
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.
Key Metrics
Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees